Chris Robillard

Chris Robillard joined Crinetics as chief business officer in 2022. Mr. Robillard brings more than a decade of experience designing and implementing corporate development strategies to capitalize on growth opportunities for biopharmaceutical companies. Before joining Crinetics, Mr. Robillard served as VP and head of business development for Goldfinch Bio, where he worked with leaders across the organization to develop the corporate development strategy that incorporated partnering and funding opportunities. Prior to that, at Karyopharm Therapeutics, he led business development and corporate strategy efforts, driving international expansion while transitioning from a clinical to commercial company. Earlier in his career, Mr. Robillard held senior positions in business development at Baxalta and finance at Cubist.

Mr. Robillard earned a Bachelor of Science in finance from Lehigh University and a Master of Business Administration from Pepperdine University.